In this study, we report the characterization of the anti-tumor activity and underlying mechanisms of a novel HDAC8 inhibitor, (E)-N-hydroxy-4-methoxy-2-(3,4-methylenedioxyphenyl)cinnamide (HMC) (Figure 1A and Figure S1) [14], in breast cancer cells. This evidence concerns the gene HDAC8 and breast carcinoma.